Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (Nasdaq: ENSC) is a clinical-stage pharmaceutical company developing abuse-deterrent medications targeting opioid and stimulant drug classes through its proprietary TAAP and MPAR platform technologies. The company filed an 8-K with the SEC on November 30, 2020, representing a material disclosure event tied to its pursuit of public-market status via a special purpose acquisition company. Ensysce operates in the pharmaceutical and biotechnology sector and reached Nasdaq through a SPAC merger, with the 2020 filing period placing it squarely within one of the most active years for healthcare and life sciences blank-check vehicles. For complete filing history, sponsor details, and deal analytics on ENSC and every active SPAC in the market, sign up for full access at SpacDesk.